Literature DB >> 20728571

Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease.

Ayako Suzuki1, Manal F Abdelmalek, Aynur Unalp-Arida, Katherine Yates, Arun Sanyal, Cynthia Guy, Anna Mae Diehl.   

Abstract

BACKGROUND & AIMS: In overnourished individuals, impaired peripheral fat storage (ie, reduced fat mass in extremities) can increase delivery of surplus calories to the organs other than peripheral adipose tissues, including the liver (ie, lipid overload), and facilitate disease progression in patients with nonalcoholic fatty liver disease (NAFLD). We investigated whether peripheral and/or abdominal adipose depot size correlates with stage of hepatic fibrosis in patients with NAFLD in sex- and/or menopausal stage-specific manners.
METHODS: We performed a cross-sectional analysis of 537 adult patients with NAFLD. Peripheral adipose depot size was defined as the sum of z-scores of 2 anthropometric parameters (middle upper arm circumference and hip circumference, relative to total body size) and expressed as extremity size. Abdominal adipose depot size was defined as waist circumference. Peripheral and abdominal adipose depot sizes were associated with fibrosis stage(s) (F0-F4) using multivariable analyses separately for men and pre- and post-menopausal women.
RESULTS: After adjusting for caloric intake and energy expenditure during physical activity (MET; hours/week), peripheral and/or abdominal adipose depot sizes were differentially associated with fibrosis stages in men and pre- and post-menopausal women. Men with smaller extremity size, premenopausal women with larger extremity size, and postmenopausal women with larger abdominal size were more likely to have higher stages of fibrosis.
CONCLUSIONS: In patients with NAFLD, regional anthropometric measures are associated with fibrosis severity in a sex- and menopausal stage-specific manner. Unlike premenopausal women, men with NAFLD who have small peripheral adipose depots are at an increased risk of having advanced fibrosis.
Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20728571      PMCID: PMC3089422          DOI: 10.1016/j.cgh.2010.08.005

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  34 in total

1.  Compendium of physical activities: an update of activity codes and MET intensities.

Authors:  B E Ainsworth; W L Haskell; M C Whitt; M L Irwin; A M Swartz; S J Strath; W L O'Brien; D R Bassett; K H Schmitz; P O Emplaincourt; D R Jacobs; A S Leon
Journal:  Med Sci Sports Exerc       Date:  2000-09       Impact factor: 5.411

2.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

Authors:  Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

3.  Nonalcoholic steatohepatitis clinical research network.

Authors: 
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

4.  Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background.

Authors:  Sei-Ichiro Kojima; Norihito Watanabe; Makoto Numata; Tetsuhei Ogawa; Shohei Matsuzaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

Review 5.  Role of estrogens in adipocyte development and function.

Authors:  Paul S Cooke; Afia Naaz
Journal:  Exp Biol Med (Maywood)       Date:  2004-12

Review 6.  The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity.

Authors:  R L Weinsier; G R Hunter; A F Heini; M I Goran; S M Sell
Journal:  Am J Med       Date:  1998-08       Impact factor: 4.965

7.  A data-based approach to diet questionnaire design and testing.

Authors:  G Block; A M Hartman; C M Dresser; M D Carroll; J Gannon; L Gardner
Journal:  Am J Epidemiol       Date:  1986-09       Impact factor: 4.897

8.  A review of goodness of fit statistics for use in the development of logistic regression models.

Authors:  S Lemeshow; D W Hosmer
Journal:  Am J Epidemiol       Date:  1982-01       Impact factor: 4.897

9.  Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II.

Authors:  J B Saunders; O G Aasland; T F Babor; J R de la Fuente; M Grant
Journal:  Addiction       Date:  1993-06       Impact factor: 6.526

Review 10.  Lipid overload and overflow: metabolic trauma and the metabolic syndrome.

Authors:  Roger H Unger
Journal:  Trends Endocrinol Metab       Date:  2003-11       Impact factor: 12.015

View more
  11 in total

1.  NASH in Special Populations.

Authors:  Ayako Suzuki
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-04

2.  Association between puberty and features of nonalcoholic fatty liver disease.

Authors:  Ayako Suzuki; Manal F Abdelmalek; Jeffrey B Schwimmer; Joel E Lavine; Ann O Scheimann; Aynur Unalp-Arida; Katherine P Yates; Arun J Sanyal; Cynthia D Guy; Anna Mae Diehl
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-14       Impact factor: 11.382

Review 3.  Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones.

Authors:  K Pafili; S A Paschou; E Armeni; S A Polyzos; D G Goulis; I Lambrinoudaki
Journal:  J Endocrinol Invest       Date:  2022-03-18       Impact factor: 5.467

4.  Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.

Authors:  Ju Dong Yang; Manal F Abdelmalek; Cynthia D Guy; Ryan M Gill; Joel E Lavine; Katherine Yates; Jagpal Klair; Norah A Terrault; Jeanne M Clark; Aynur Unalp-Arida; Anna Mae Diehl; Ayako Suzuki
Journal:  Clin Gastroenterol Hepatol       Date:  2016-08-12       Impact factor: 11.382

5.  NAFLD in women: Unique pathways, biomarkers and therapeutic opportunities.

Authors:  Liyun Yuan; Ani Kardashian; Monika Sarkar
Journal:  Curr Hepatol Rep       Date:  2019-11-18

Review 6.  NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Enrica Baldelli; Alessandra Marrazzo; Dante Romagnoli; Amedeo Lonardo
Journal:  Adv Ther       Date:  2017-05-19       Impact factor: 3.845

7.  Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease.

Authors:  Marta Hernández-Conde; Elba Llop; Carlos Fernández Carrillo; Beatriz Tormo; Javier Abad; Luis Rodriguez; Christie Perelló; Marta López Gomez; José Luis Martínez-Porras; Natalia Fernández Puga; Maria Trapero-Marugan; Enrique Fraga; Carlos Ferre Aracil; José Luis Calleja Panero
Journal:  World J Gastroenterol       Date:  2020-11-14       Impact factor: 5.742

8.  The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008-2011).

Authors:  Hyun Min Kim; Yong-Ho Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2021-11-23

Review 9.  NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment.

Authors:  Johanna K DiStefano
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736

10.  Tissue-specific pathways and networks underlying sexual dimorphism in non-alcoholic fatty liver disease.

Authors:  Zeyneb Kurt; Rio Barrere-Cain; Jonnby LaGuardia; Margarete Mehrabian; Calvin Pan; Simon T Hui; Frode Norheim; Zhiqiang Zhou; Yehudit Hasin; Aldons J Lusis; Xia Yang
Journal:  Biol Sex Differ       Date:  2018-10-22       Impact factor: 5.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.